Mr Thomas Mitchell, FRCS | Clinician Scientist Fellow

Mitchell, Thomas

Tom Mitchell's research programme focusses on understanding how kidney tumours initiate, evolve and evade treatment. The motivation for this body of work is provided by the patients he treats as a Consultant Urologist at Addenbrooke's Hospital where he specialises in the surgical treatment of kidney cancer.

“I am interested in deciphering how tumours evolve over many decades from normal healthy cells. Increasingly, my interest lies not only in understanding and modelling somatic mutations acquired in the developing tumour, but also how these cancer cells interact with their multi-cellular micro-environment. The over-arching aim of these approaches is to improve the clinical management of patients with cancer.”

Publications

  • Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.

    Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR et al.

    Cell 2018;173;3;611-623.e17

  • Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors.

    Young MD, Mitchell TJ, Vieira Braga FA, Tran MGB, Stewart BJ et al.

    Science (New York, N.Y.) 2018;361;6402;594-599

  • Embryonal precursors of Wilms tumor.

    Coorens THH, Treger TD, Al-Saadi R, Moore L, Tran MGB et al.

    Science (New York, N.Y.) 2019;366;6470;1247-1251

  • Spatiotemporal immune zonation of the human kidney.

    Stewart BJ, Ferdinand JR, Young MD, Mitchell TJ, Loudon KW et al.

    Science (New York, N.Y.) 2019;365;6460;1461-1466

  • Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

    Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I et al.

    Nature genetics 2018;50;5;682-692

  • The evolutionary history of 2,658 cancers.

    Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S et al.

    Nature 2020;578;7793;122-128

  • Pan-cancer analysis of whole genomes.

    ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium

    Nature 2020;578;7793;82-93

  • Intra-tumour diversification in colorectal cancer at the single-cell level.

    Roerink SF, Sasaki N, Lee-Six H, Young MD, Alexandrov LB et al.

    Nature 2018;556;7702;457-462

  • Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.

    Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S et al.

    Cell 2018;173;3;595-610.e11

  • Downregulation of androgen receptor transcription by promoter g-quadruplex stabilization as a potential alternative treatment for castrate-resistant prostate cancer.

    Mitchell T, Ramos-Montoya A, Di Antonio M, Murat P, Ohnmacht S et al.

    Biochemistry 2013;52;8;1429-36

  • Inferring structural variant cancer cell fraction.

    Cmero M, Yuan K, Ong CS, Schröder J, PCAWG Evolution and Heterogeneity Working Group et al.

    Nature communications 2020;11;1;730

  • The evolutionary history of 2,658 cancers.

    Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S et al.

    Nature 2020;578;7793;122-128

  • Pan-cancer analysis of whole genomes.

    ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium

    Nature 2020;578;7793;82-93

  • Embryonal precursors of Wilms tumor.

    Coorens THH, Treger TD, Al-Saadi R, Moore L, Tran MGB et al.

    Science (New York, N.Y.) 2019;366;6470;1247-1251

  • Spatiotemporal immune zonation of the human kidney.

    Stewart BJ, Ferdinand JR, Young MD, Mitchell TJ, Loudon KW et al.

    Science (New York, N.Y.) 2019;365;6460;1461-1466

  • Genomic landscape and chronological reconstruction of driver events in multiple myeloma.

    Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D et al.

    Nature communications 2019;10;1;3835

  • Genomics and clinical correlates of renal cell carcinoma.

    Mitchell TJ, Rossi SH, Klatte T and Stewart GD

    World journal of urology 2018;36;12;1899-1911

  • Neutral tumor evolution?

    Tarabichi M, Martincorena I, Gerstung M, Leroi AM, Markowetz F et al.

    Nature genetics 2018;50;12;1630-1633

  • Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors.

    Young MD, Mitchell TJ, Vieira Braga FA, Tran MGB, Stewart BJ et al.

    Science (New York, N.Y.) 2018;361;6402;594-599

  • Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

    Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I et al.

    Nature genetics 2018;50;5;682-692

  • Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.

    Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S et al.

    Cell 2018;173;3;595-610.e11

  • Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.

    Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR et al.

    Cell 2018;173;3;611-623.e17

  • Intra-tumour diversification in colorectal cancer at the single-cell level.

    Roerink SF, Sasaki N, Lee-Six H, Young MD, Alexandrov LB et al.

    Nature 2018;556;7702;457-462

  • Downregulation of androgen receptor transcription by promoter g-quadruplex stabilization as a potential alternative treatment for castrate-resistant prostate cancer.

    Mitchell T, Ramos-Montoya A, Di Antonio M, Murat P, Ohnmacht S et al.

    Biochemistry 2013;52;8;1429-36

  • Acute abdomen caused by bladder rupture attributable to neurogenic bladder dysfunction following a stroke: a case report.

    Mitchell T, Al-Hayek S, Patel B, Court F and Gilbert H

    Journal of medical case reports 2011;5;254

  • Intradermal ballistic delivery of micro-particles into excised human skin for pharmaceutical applications.

    Kendall M, Mitchell T and Wrighton-Smith P

    Journal of biomechanics 2004;37;11;1733-41

  • Effects of relative humidity and ambient temperature on the ballistic delivery of micro-particles to excised porcine skin.

    Kendall M, Rishworth S, Carter F and Mitchell T

    The Journal of investigative dermatology 2004;122;3;739-46

Career/Research Highlights

Mitchell, Thomas
Thomas's Timeline
2018

Cancer Research UK/ Royal College of Surgeons Clinician Scientist Fellowship, Wellcome Sanger Institute

Honorary Consultant Urologist, Addenbrooke's Hospital

2016

FRCS (Urol): Fellowship of the Royal College of Surgeons of England

2014

Academic Clinical Lecturer, Cambridge University

Honorary Specialist Registrar, Addenbrooke's Hospital

2011

Academic Clinical Fellow, Cambridge University

2009

Core Surgical Trainee, Gloucestershire NHS Foundation Trust

2007

Foundation Doctor, Gloucestershire NHS Foundation Trusts

BMBCh, Bachelor of Medicine and Surgery, University of Oxford

2003

DPhil, Doctorate of Philosophy in Engineering Science, University of Oxford